The smartphone-enabled mobile device rapidly determines the heart’s rate-corrected QT interval, or QTc — a measurement used to evaluate the health of the heart’s electrical recharging system. Patients with a prolonged QTc can experience rapid heartbeats, and in some cases, sudden cardiac death.
Researchers assessed AliveCor’s KardiaMobile 6L EKG device by comparing it to a 12-lead EKG, which is typically used to evaluate QTc. Mayo Clinic cardiology researchers used more than 1.6 million 12-lead EKGs to train and validate the mobile device on how to effectively measure the QTc and detect prolongation. The findings, published in Circulation, showed the mobile device had an 80 percent sensitivity, meaning fewer cases of QTc prolongation were missed, and 94.4 percent specificity, indicating the device was highly accurate in predicting who did not have a prolonged QTc.
“Akin to a glucose meter for diabetics, for example, this QT meter will provide an early warning system, enabling patients with congenital or acquired long QT syndrome to be identified and potentially lifesaving adjustments to their medications and electrolytes to be made,” said Michael Ackerman, MD, PhD, study author and Mayo Clinic cardiologist.
To read the news release, click here.
To view the study findings, click here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.